 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...2324252627282930313233...3839» |
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (Kalden) - Mar 4, 2020 - Abstract #EULAR2020EULAR_255;
Our findings indicate a potential role of fMRI imaging of the brain to further understand disease activity perception in RA patients. Figure 1.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] THE IMPACT OF PERSISTENT INFLAMMATORY CHANGES ON PREVALENCE OF FATTY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: 4-YEAR MRI RESULTS FROM RAPID-AXSPA (Amor) - Mar 4, 2020 - Abstract #EULAR2020EULAR_218;
P3
Reduction of inflammation by Wk 12 mitigated the risk of FL over the long-term, indicating the importance of early, effective and long-term treatment targeting inflammation. Similarly, a complete and persistent reduction of inflammation appears to be critical in these patients.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION? (Amor) - Mar 4, 2020 - Abstract #EULAR2020EULAR_217;
P3
The results of C-OPTIMISE indicate that a reduced maintenance dose is suitable for pts with axSpA who achieve sustained remission following 1 year of CZP treatment, regardless of axSpA subpopulation, gender or age. Complete treatment withdrawal is not recommended due to the high risk of flare.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Associations of vascular pathophysiology and bone metabolism in anti-TNF- treated rheumatoid arthritis and ankylosing spondylitis patients (Jubilee Hall KU Leuven) - Feb 28, 2020 - Abstract #EWRR2020EWRR_178;
In our study of anti-TNF treated RA and AS patients, vascular and bone parameters showed numerous correlations. The therapy was clinically effective, it halted further bone loss over 1 year and reduced the production of angiogenic markers.
- | Retrospective data, Journal: Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. (Pubmed Central) - Feb 25, 2020
The therapy was clinically effective, it halted further bone loss over 1 year and reduced the production of angiogenic markers. Biologicals and apremilast may serve as second-line options for treatment of PPP and should be further evaluated.
- || Clinical, Journal: Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. (Pubmed Central) - Feb 25, 2020
P4
In this study, we observed an apparent benefit of IL-1 inhibition in participants with RA and T2D, reaching the therapeutic targets of both diseases. Our results suggest the concept that IL-1 inhibition may be considered a targeted treatment for RA and T2D.
- | Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Journal: Primary Cutaneous Nocardiosis in a Man Treated With Certolizumab. (Pubmed Central) - Feb 24, 2020
Our results suggest the concept that IL-1 inhibition may be considered a targeted treatment for RA and T2D. No abstract available
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: CIMcare: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) - Feb 23, 2020
P3, N=150, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
No abstract available Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Apr 2023 --> Jul 2023
- Persistence of Biologics for the Treatment of Psoriatic Arthritis: Data From a Large Longitudinal Cohort () - Feb 19, 2020 - Abstract #CRAAHPA2020CRA-AHPA_427;
When used as second drug, TNFi had lower survival rates while secukinumab had higher values. It is important to note however that not all the drugs were available in 1999 therefore the number of options available may have influenced the choice of therapy and therefore drug persistence.
- Drug Retention of Tumor Necrosis Factor Inhibitors Compared to Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis () - Feb 19, 2020 - Abstract #CRAAHPA2020CRA-AHPA_399;
Most of the TNFi use was etanercept (63.4%), adalimumab (25.3%), and Certolizumab (7.9%) while 99% of JAK inhibitor use was from tofacitinib. More data are needed to determine if there are retention differences between the two groups over a longer observation period.
- The Effect of TNF-Inhibitor Therapy on Structural Progression in Ankylosing Spondylitis Patients: A Systematic Review and Meta-Analysis () - Feb 19, 2020 - Abstract #CRAAHPA2020CRA-AHPA_321;
This systematic review confirmed that mSASSS has good-to-excellent inter-rater reliability in AS. In addition, the narrative analysis of the data from 21 studies indicated that studies with greater than four years of follow up had reduced structural radiographic progression with TNFi use in AS patients.
- Time to Discontinuation of Tofacitinib and TNF inhibitors in Rheumatoid Arthritis Patients with and without Methotrexate: Data from A Rheumatoid Arthritis Cohort () - Feb 19, 2020 - Abstract #CRAAHPA2020CRA-AHPA_289;
In this real world data study, we found that TOFA retention is similar in patients with and without MTX, while patients treated with TNFi and MTX remained on treatment longer than those treated without MTX. Merging data with other RA registries in Canada is proposed to increase study power and to provide more robust results.
- Decomposition Analysis of Spending and Price Trends for Biologic Disease-Modifying Anti-Rheumatic Drugs by Public Payers in Canada and the United States () - Feb 19, 2020 - Abstract #CRAAHPA2020CRA-AHPA_246;
Individual- and pan-Canadian negotiations with drug manufacturers likely helped BC (and other provinces) avoid the steep post-market price hikes faced by US publicpayers. However, further measures (i.e. expanded use of lower-priced biosimilars) are needed to help manage ongoing rises in public spending from increasing numbers of bDMARD recipients.
- ||| Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
New #AusPAR for #Cimzia (#certolizumab pegol) for the treatment of #non-radiographic axial spondyloarthritis https://t.co/25cpLYVuAL (Twitter) - Feb 18, 2020
- | Journal: Two-year adherence and costs for biologic therapy for rheumatoid arthritis. (Pubmed Central) - Feb 16, 2020
However, further measures (i.e. expanded use of lower-priced biosimilars) are needed to help manage ongoing rises in public spending from increasing numbers of bDMARD recipients. Adherence to the first bDMARD was suboptimal even in effectively treated patients, suggesting opportunities to improve adherence in patients with RA initiating biologics.
- | Journal: Cost of biologic treatment persistence or switching in rheumatoid arthritis. (Pubmed Central) - Feb 16, 2020
Patients with RA who switched biologic therapy incurred higher 1-year total postswitch healthcare costs compared with patients who were persistent on the index biologic. Healthcare costs were lowest for patients who started on etanercept, particularly those who persisted on etanercept.
- | Review, Journal: Drugs for psoriatic arthritis. (Pubmed Central) - Feb 15, 2020
Healthcare costs were lowest for patients who started on etanercept, particularly those who persisted on etanercept. No abstract available
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Enrollment change: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Feb 13, 2020
P4, N=208, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
No abstract available N=400 --> 208
- Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies () - Feb 9, 2020 - Abstract #WCDC2020WCDC_168;
N=400 --> 208 Abstract not available.
- Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study () - Feb 9, 2020 - Abstract #WCDC2020WCDC_165;
Abstract not available. Abstract not available.
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_927;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- |||| Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical: I discuss all options w my pts; I tell them Certolizumab doesn’t cross the placenta; other TNFi do, but we have solid data from #PIANO & other studies that this does NOT⬆️ risk of congenital malformations, or infection in the newborn (no live vaccine @yr1 though). #SharedDecision (Twitter) - Feb 8, 2020
- || Clinical, Journal: Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. (Pubmed Central) - Feb 7, 2020
Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053 Preoperative exposure to anti-TNF biologic therapy does not add to overall or infectious 30-day postoperative morbidity in pediatric CD patients.
- |||| Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical: If candidate for anti-TNF (and pending no barriers to getting the medication), do you recommend Cimzia first-line in women who anticipate pregnancy in the future? (Twitter) - Feb 6, 2020
- | Journal: Inflammatory bowel disease and targeted oral anti-TNFα therapy. (Pubmed Central) - Jan 31, 2020
Several oral anti-TNFα agents have been investigated with success but are not yet in general clinical use. This partially reflects the fact that the oral administration of antibodies has many barriers including the harsh environment of the GI tract and the presence of enzymes including pepsin, trypsin and chymotrypsin in the intestine which provide significant challenges to targeted oral therapy.
- || Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Observational data, Journal: Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study. (Pubmed Central) - Jan 30, 2020
This partially reflects the fact that the oral administration of antibodies has many barriers including the harsh environment of the GI tract and the presence of enzymes including pepsin, trypsin and chymotrypsin in the intestine which provide significant challenges to targeted oral therapy. CZP has a positive impact on productivity and social participation in patients with RA in the Belgian daily practice setting, with safety and efficacy profiles that mirror those observed in the trial setting.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: C-VIEW: A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (clinicaltrials.gov) - Jan 30, 2020
P4, N=89, Completed, Sponsor: UCB Biopharma S.P.R.L.
CZP has a positive impact on productivity and social participation in patients with RA in the Belgian daily practice setting, with safety and efficacy profiles that mirror those observed in the trial setting. Active, not recruiting --> Completed
- || Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis. (Pubmed Central) - Jan 28, 2020
Active, not recruiting --> Completed No abstract available
- | Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Journal: Certolizumab (Pubmed Central) - Jan 28, 2020
No abstract available No abstract available
- || Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
22 yo M law student on IFX since 2013, slow progression fibrostenosing ileal CD. Post-op ICR x 1 mo. BC refuses Humira, wants me to rx Entyvio or Cimzia first. WTF? WhyTryandFail?? (Twitter) - Jan 28, 2020
- EVALUATION OF BIOLOGIC TREATMENT PATTERNS AMONG CROHN’S DISEASE PATIENTS USING THREE LARGE UNITED STATES CLAIMS DATABASES () - Jan 28, 2020 - Abstract #DDW2020DDW_3119;
Introduction: Real-world evidence on treatment patterns among Crohn’s disease (CD) patients using biologics remains limited, particularly among ustekinumab (UST) patients...Patients (aged 18-64 years) were required to have ≥1 claim for CD and ≥1 claim for biologics (UST, vedolizumab [VDZ], infliximab [IFX], certolizumab pegol [CZP], or adalimumab [ADA]) during the identification period (IQVIA: 09/26/16-12/31/17; MarketScan: 09/26/16-09/30/17; Optum: 09/26/16-03/31/18)... Among CD patients, unadjusted persistence was numerically higher in the UST cohort with consistent trends in the bio-naïve and bio-experienced subsets.
- INFLAMMATORY BOWEL DISEASE AND LUNG CANCER: RISK AND ROLE OF IBD THERAPY () - Jan 28, 2020 - Abstract #DDW2020DDW_3012;
Patients receiving treatment for IBD are at lower risk to develop lung cancer especially on biological agents. This may be due to higher clinical remission and inflammation control in patients receiving treatment.
- DISEASE BURDEN AND OUTCOMES OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH HIV INFECTION IN THE UNITED STATES: A POPULATION BASED STUDY () - Jan 28, 2020 - Abstract #DDW2020DDW_3005;
This specific population needs more care given their worse disease outcomes and higher medical burden. More studies are needed to further delineate the clinical association and effect of HIV therapy on disease outcome.
- INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNOBIOLOGIC THERAPY ARE LESS LIKELY TO DEVELOP COLORECTAL CANCER: ANALYSIS OF THE EXPLORYS DATABASE () - Jan 28, 2020 - Abstract #DDW2020DDW_2664;
In this large database, IBD patients who were treated with immunobiologics were less likely to develop CRC. Further studies are required to determine if immunobiogics are chemoprotective by inflammation control and mucosal healing.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
FAECAL CALPROTECTIN AS THERAPEUTIC TARGET IN PATIENTS WITH CROHN’S DISEASE TREATED WITH ANTI-TNF: A META-ANALYSIS OF INDIVIDUAL DATA () - Jan 28, 2020 - Abstract #DDW2020DDW_2608;
The combination of clinical remission, CRP normalization and FCal improvement should be a therapeutic target in patients with CD. Our work highlighted the need of international standardization of Fcal measurement.
- META-ANALYSIS OF THE INCIDENCE OF DERMATOLOGICAL REACTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ANTI-TNF () - Jan 28, 2020 - Abstract #DDW2020DDW_2545;
The most commonly reported reaction is psoriasis/psoriasiform reaction. Clinicians should be vigilant to dermatological side effects following treatment of IBD with anti-TNF.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
PATIENTS WITH CROHN’S DISEASE AT RISK OF SUBTHERAPEUTIC CERTOLIZUMAB PEGOL DRUG EXPOSURE CAN BE IDENTIFIED PRIOR TO INITIATION OF THERAPY () - Jan 28, 2020 - Abstract #DDW2020DDW_2205;
Clearance can be calculated using baseline clinical variables and would allow for identification of patients for whom therapeutic CZP concentrations may be achieved with current approved dosing. Therapeutic drug monitoring can be implemented in patients at risk for accelerated clearance to assess therapeutic drug exposure during induction which may increase the likelihood of treatment success.
- TRENDS IN COMMON LABORATORY MARKERS DURING PREGNANCY IN WOMEN WITH QUIESCENT IBD. () - Jan 28, 2020 - Abstract #DDW2020DDW_2179;
Abnormal changes in routinely monitored biomarkers of active inflammation are commonly observed during pregnancy even in women with quiescent IBD. Such findings suggest these changes are common physiologic responses to pregnancy and should be interpreted in the context of clinical symptoms.
- RISK FACTORS FOR NON-ADHERENCE TO SELF-INJECTABLE BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: A VALIDATION COHORT STUDY () - Jan 28, 2020 - Abstract #DDW2020DDW_2102;
In pts with moderate to severe CD on self-injectable biologic medication, several previously described cumulative risk factors for non-adherence (narcotic use, psychiatric diagnosis history, prior biologic medication use, and smoking) were validated and remained significant. Non-adherence increased the risk of hospitalization.
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: CIMcare: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) - Jan 27, 2020
P3, N=150, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Non-adherence increased the risk of hospitalization. Not yet recruiting --> Recruiting
- || Clinical, Journal: Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. (Pubmed Central) - Jan 27, 2020
Not yet recruiting --> Recruiting In axial spondyloarthritis, drug survival with standard doses of different TNF inhibitors is comparable.
- || Clinical, Retrospective data, Journal: Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. (Pubmed Central) - Jan 25, 2020
In axial spondyloarthritis, drug survival with standard doses of different TNF inhibitors is comparable. ABT showed lowest discontinuation rate by lack of effectiveness and by toxic adverse events, which lead to highest overall retention rates (excluding non-toxic reasons and remission) among seven bDMARDs in adjusted model of elderly RA patients.
- |||| bimekizumab (UCB4940) / UCB, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical: I missed this, but it is actually quite interesting! Thanks to @rheumnow! Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study https://t.co/0L91ALRs6R (Twitter) - Jan 21, 2020
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Observational data, Journal: Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. (Pubmed Central) - Jan 21, 2020
ABT showed lowest discontinuation rate by lack of effectiveness and by toxic adverse events, which lead to highest overall retention rates (excluding non-toxic reasons and remission) among seven bDMARDs in adjusted model of elderly RA patients. CDAI non-response at M3 is a predictor of failure to achieve the therapeutic target of LDA at M12 in patients with RA initiating treatment with CZP.
- | Journal: Management of large-vessel vasculitis. (Pubmed Central) - Jan 17, 2020
Despite recent randomized controlled trials with biologic agents, management of large-vessel vasculitis largely depends on observational studies. Well designed controlled trials using validated outcome measures in large number of patients, identification of biologic markers that could guide the choice of targeted treatments, and standardization of disease assessment including imaging modalities are unmet needs for the management of large-vessel vasculitis.
- | Enrollment change, Trial primary completion date: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) - Jan 14, 2020
P4, N=30, Recruiting, Sponsor: Karolinska Institutet
Well designed controlled trials using validated outcome measures in large number of patients, identification of biologic markers that could guide the choice of targeted treatments, and standardization of disease assessment including imaging modalities are unmet needs for the management of large-vessel vasculitis. N=500 --> 30 | Trial primary completion date: Jun 2020 --> Mar 2021
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Jan 13, 2020
P4, N=812, Active, not recruiting, Sponsor: Karolinska Institutet
N=500 --> 30 | Trial primary completion date: Jun 2020 --> Mar 2021 Trial primary completion date: Jun 2019 --> Oct 2021
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Journal: Anti-TNF, a magic bullet in cancer immunotherapy? (Pubmed Central) - Jan 11, 2020
These include colitis, which can be treated with anti-tumor necrosis factor (TNF) antibodies such as Infliximab...Herein, (i) we discuss the scientific rationale for combining anti-TNF and ICB in cancer patients, (ii) comment on the paper published by Badran et al. and (iii) provide the TICIMEL clinical trial design.
- || Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Clinical, Journal: A 52-Week Randomized Placebo-Controlled Trial of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis. (Pubmed Central) - Jan 8, 2020
P3
Adding CZP to background medication is superior to adding placebo in patients with active nr-axSpA. These results indicate that remission in nr-axSpA treated without biologics occurs infrequently, demonstrating the need for treatment beyond non-biologic therapy.
- Prevalence association between HPV and fistulising perianal Crohn’s disease (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1672;
The subtypes more frequently identified were HPV-11 (15.5%), HPV-16 (8.9%) and HPV-53 (6.7%).Conclusion This study shows a high point-prevalence of HPV, specially high-risk subtypes in fistulising PCD population. More studies are necessary to define a screening for cancer in this population.